Literature DB >> 2015422

Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat.

M A Barrand1, B A Callingham.   

Abstract

1. 59Fe absorption from the novel iron compound, ferric maltol, was studied in rats pretreated twice daily for two weeks with non-radioactive ferric maltol in oral doses containing 7 mg elemental iron. Tissue accumulation of 59Fe 2 h after administration of radioactive ferric maltol into the stomach was significantly lower in iron pretreated animals than in saline-treated controls. 2. 59Fe uptake from ferric maltol into isolated fragments of ileum and of duodenum was of similar magnitude in control animals but in iron-treated animals, duodenal uptake was significantly lower than that of the ileum. 3. Absorption of 59Fe was also investigated in anaesthetized rats after intestinal perfusion with saline (controls) or with 5 mM chenodeoxycholate to render the intestines more permeable. 4. Changes in permeability of the small intestine were monitored by estimating the amount of [14C]-mannitol absorbed and fluid secreted with reference to the non-absorbable [3H]-inulin in the perfusate effluents. 5. Despite the increased permeability of the intestines after bile salt treatment, there was little difference from control in the tissue accumulation of 59Fe from ferric maltol 2 h after intraduodenal administration. However 59Fe absorption from ferrous sulphate was significantly increased after bile salt treatment. 6. Gel filtration profiles of plasma made 5 and 60 min after intraduodenal administration of [59Fe]-ferric [3H]-maltol demonstrated that metal and ligand do not enter the circulation as the complex even when intestinal permeability is increased. 7. Uptake of 59Fe was investigated in isolated fragments of rat small intestine after saline or bile salt perfusion. Although 59Fe uptake from ferric maltol was somewhat greater in the bile salt-treated intestinal fragments, saturable kinetics were still observed. By contrast, "Fe uptake from ferrous sulphate: ascorbate was greatly enhanced by bile salt pretreatment and a very large diffusional component of uptake was evident. 8. It is concluded that iron uptake from ferric maltol may well be under endogenous regulatory control even in damaged intestines, so it is unlikely that this novel iron compound can bring about iron overload when administered orally.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015422      PMCID: PMC1918048          DOI: 10.1111/j.1476-5381.1991.tb12187.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Assay of intestinal disaccharidases.

Authors:  A Dahlqvist
Journal:  Anal Biochem       Date:  1968-01       Impact factor: 3.365

2.  Blocking of iron absorption by a preliminary oral dose of iron.

Authors:  M A O'Neil-Cutting; W H Crosby
Journal:  Arch Intern Med       Date:  1987-03

3.  The effect of short-term exposure to low-iron diets on the mucosal processing of ionic iron.

Authors:  R W Topham; S A Joslin; J S Prince
Journal:  Biochem Biophys Res Commun       Date:  1985-12-31       Impact factor: 3.575

4.  Studies on the nature of the increased monoamine oxidase activity in the rat heart after adrenalectomy.

Authors:  B A Callingham; R Laverty
Journal:  J Pharm Pharmacol       Date:  1973-12       Impact factor: 3.765

5.  16,16-Dimethyl prostaglandin E2 reduced chenodeoxycholate-induced small intestinal mucosal injury in the rat.

Authors:  R A Erickson; A Tarnawski; W J Krause
Journal:  J Lab Clin Med       Date:  1987-10

6.  In vivo studies on the relationship between intestinal iron (Fe3+) absorption, hypoxia and erythropoiesis in the mouse.

Authors:  K B Raja; R J Simpson; M J Pippard; T J Peters
Journal:  Br J Haematol       Date:  1988-03       Impact factor: 6.998

7.  Regional specificity of iron uptake by small intestinal brush-border membranes from normal and iron-deficient mice.

Authors:  A Muir; U Hopfer
Journal:  Am J Physiol       Date:  1985-03

8.  Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol.

Authors:  J A Levey; M A Barrand; B A Callingham; R C Hider
Journal:  Biochem Pharmacol       Date:  1988-05-15       Impact factor: 5.858

9.  Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine.

Authors:  M A Barrand; B A Callingham; R C Hider
Journal:  J Pharm Pharmacol       Date:  1987-03       Impact factor: 3.765

10.  The importance of reductive mechanisms for intestinal uptake of iron from ferric maltol and ferric nitrilotriacetic acid (NTA).

Authors:  M A Barrand; R C Hider; B A Callingham
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

View more
  4 in total

1.  Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Authors:  Bernd Bokemeyer; Annette Krummenerl; Christian Maaser; Stefanie Howaldt; Michael Mroß; Nick Mallard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

3.  Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Authors:  C Schmidt; T Ahmad; Z Tulassay; D C Baumgart; B Bokemeyer; S Howaldt; A Stallmach; C Büning
Journal:  Aliment Pharmacol Ther       Date:  2016-05-29       Impact factor: 8.171

4.  Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Authors:  Stefanie Howaldt; Eugeni Domènech; Nicholas Martinez; Carsten Schmidt; Bernd Bokemeyer
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.